10,387 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Purchased by Sherbrooke Park Advisers LLC

Sherbrooke Park Advisers LLC acquired a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,387 shares of the biopharmaceutical company's stock, valued at approximately $437,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Ultragenyx Pharmaceutical by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company's stock valued at $422,167,000 after buying an additional 89,389 shares during the period. Invesco Ltd. grew its holdings in Ultragenyx Pharmaceutical by 1.5% during the fourth quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock valued at $71,509,000 after purchasing an additional 25,487 shares during the period. Alliancebernstein L.P. increased its stake in Ultragenyx Pharmaceutical by 5.3% in the fourth quarter. Alliancebernstein L.P. now owns 1,627,932 shares of the biopharmaceutical company's stock valued at $68,487,000 after purchasing an additional 81,667 shares in the last quarter. Alyeska Investment Group L.P. raised its holdings in Ultragenyx Pharmaceutical by 23.1% in the fourth quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company's stock worth $60,570,000 after purchasing an additional 269,733 shares during the period. Finally, Point72 Asset Management L.P. boosted its position in shares of Ultragenyx Pharmaceutical by 81.0% during the fourth quarter. Point72 Asset Management L.P. now owns 1,182,877 shares of the biopharmaceutical company's stock worth $49,764,000 after purchasing an additional 529,217 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Insider Activity at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 2,990 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the sale, the executive vice president now directly owns 54,991 shares in the company, valued at approximately $2,358,014.08. This trade represents a 5.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Theodore Alan Huizenga sold 967 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the transaction, the chief accounting officer now directly owns 50,265 shares in the company, valued at approximately $2,116,156.50. This trade represents a 1.89% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 125,405 shares of company stock valued at $5,285,169. 5.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

RARE has been the subject of a number of recent analyst reports. Piper Sandler lowered their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research report on Monday, March 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Morgan Stanley boosted their price objective on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Canaccord Genuity Group lifted their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. Finally, HC Wainwright reiterated a "buy" rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $90.93.

Ultragenyx Pharmaceutical Stock Up 0.4%

Shares of NASDAQ:RARE traded up $0.15 during midday trading on Friday, reaching $35.66. The company had a trading volume of 127,941 shares, compared to its average volume of 822,774. Ultragenyx Pharmaceutical Inc. has a 1-year low of $29.59 and a 1-year high of $60.37. The stock has a market cap of $3.37 billion, a PE ratio of -5.62 and a beta of 0.34. The business's 50 day moving average price is $36.11 and its 200 day moving average price is $41.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). The company had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The firm's revenue for the quarter was up 28.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($2.03) earnings per share. On average, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.